- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on High Post-Treatment Platelet Reactivity in France
Total 26 results
-
University Hospital, Clermont-FerrandCompletedAortic Surgery and Treatment Post Operative With Paracetamol During 4 DaysFrance
-
Mon Stade Sports Medicine CentreLaboratory MOVE, Faculty of Sport Sciences, University of Poitiers, France; Public Health Foundation of MGEN, France and other collaboratorsRecruitingPhysical Activity | Life Style, Healthy | Adherence, Patient | Life Style | Cost-Benefit Analysis | Behavior and Behavior Mechanisms | Exercise Therapy | Adapted Physical Activity | Lifestyle, Sedentary | PrescriptionsFrance
-
Ronald HoffmanNational Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...CompletedHigh Risk Polycythemia Vera | High Risk Essential ThrombocythemiaUnited States, Italy, United Kingdom, France
-
Assistance Publique - Hôpitaux de ParisTerminatedANCA + Vasculitides Relapsing Either Under Corticosteroid | and Immunosuppressant Therapies or After One Year | Post Treatment.France
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, France, Canada, Germany, Australia
-
Novartis PharmaceuticalsCompletedIdiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera MyelofibrosisUnited Kingdom, Ireland, Germany, Italy, France
-
GlaxoSmithKlineActive, not recruitingNeoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) MyelofibrosisUnited States, Canada
-
Kartos Therapeutics, Inc.RecruitingPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
-
AstraZenecaUniversity of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...CompletedPrimary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia MyelofibrosisUnited States, France
-
Incyte CorporationRecruitingAnemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, France, Italy, Japan, United Kingdom, Canada
-
CTI BioPharmaCompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia MyelofibrosisUnited States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
-
Incyte CorporationCompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States
-
CTI BioPharmaTerminatedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
-
CTI BioPharmaPSI CRORecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
-
Constellation PharmaceuticalsActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
-
CTI BioPharmaTerminatedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
-
University Hospital, BrestRecruitingPolycythemia Vera | Essential Thrombocythemia | High-risk Patients | Prefibrotic/Early Primary Myelofibrosis | JAK2 V617FFrance
-
Hoffmann-La RocheCompletedPrimary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia MyelofibrosisUnited States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditionsUnited States, Canada